XML 159 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenues (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue by product and by geographic area
Revenues were as follows (in millions):
 
 
Year ended December 31, 2019
 
 
U.S.
 
ROW
 
Total
Enbrel® (etanercept)
 
$
5,050

 
$
176

 
$
5,226

Neulasta® (pegfilgrastim)
 
2,814

 
407

 
3,221

Prolia® (denosumab)
 
1,772

 
900

 
2,672

XGEVA® (denosumab)
 
1,457

 
478

 
1,935

Aranesp® (darbepoetin alfa)
 
758

 
971

 
1,729

KYPROLIS® (carfilzomib)
 
654

 
390

 
1,044

EPOGEN® (epoetin alfa)
 
867

 
—

 
867

Sensipar®/Mimpara® (cinacalcet)
 
252

 
299

 
551

Other products
 
2,907

 
2,052

 
4,959

Total product sales(1)
 
16,531

 
5,673

 
22,204

Other revenues
 
693

 
465

 
1,158

Total revenues
 
$
17,224

 
$
6,138

 
$
23,362

 
 
Year ended December 31, 2018
 
 
U.S.
 
ROW
 
Total
ENBREL
 
$
4,807

 
$
207

 
$
5,014

Neulasta®
 
3,866

 
609

 
4,475

Prolia®
 
1,500

 
791

 
2,291

Aranesp®
 
942

 
935

 
1,877

XGEVA®
 
1,338

 
448

 
1,786

Sensipar®/Mimpara®
 
1,436

 
338

 
1,774

EPOGEN®
 
1,010


—

 
1,010

KYPROLIS®
 
583

 
385

 
968

Other products
 
1,947

 
1,391

 
3,338

Total product sales(1)
 
17,429

 
5,104

 
22,533

Other revenues
 
929

 
285

 
1,214

Total revenues
 
$
18,358

 
$
5,389

 
$
23,747

 
 
Year ended December 31, 2017
 
 
U.S.
 
ROW
 
Total
ENBREL
 
$
5,206

 
$
227

 
$
5,433

Neulasta®
 
3,931

 
603

 
4,534

Aranesp®
 
1,114

 
939

 
2,053

Prolia®
 
1,272

 
696

 
1,968

Sensipar®/Mimpara®
 
1,374

 
344

 
1,718

XGEVA®
 
1,157

 
418

 
1,575

EPOGEN®
 
1,096

 
—

 
1,096

KYPROLIS®
 
562

 
273

 
835

Other products
 
1,419

 
1,164

 
2,583

Total product sales(1)
 
17,131

 
4,664

 
21,795

Other revenues
 
898

 
156

 
1,054

Total revenues
 
$
18,029

 
$
4,820

 
$
22,849

____________ 
(1) 
Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2019, 2018 and 2017.
Revenues earned from major customers Certain information with respect to these customers was as follows (dollar amounts in millions):
 
Years ended December 31,
 
2019
 
2018
 
2017
AmerisourceBergen Corporation:
 
 
 
 
 
Gross product sales
$
12,301

 
$
12,091

 
$
10,742

% of total gross revenues
33
%
 
33
%
 
31
%
McKesson Corporation:
 
 
 
 
 
Gross product sales
$
11,795

 
$
11,434

 
10,625

% of total gross revenues
31
%
 
31
%
 
30
%
Cardinal Health, Inc.:
 
 
 
 
 
Gross product sales
$
6,538

 
$
7,475

 
$
7,049

% of total gross revenues
17
%
 
20
%
 
20
%